본문으로 건너뛰기
← 뒤로

Durable Disease Control With Nivolumab in Malignant Epithelioid Angiomyolipoma: A Case Report.

증례보고 1/5 보강
IJU case reports 📖 저널 OA 100% 2022: 1/1 OA 2025: 9/9 OA 2026: 25/25 OA 2022~2026 2026 Vol.9(2) p. e70170 OA
Retraction 확인
출처

Shimoda H, Fukuda S, Yafuso D, Yamamoto K, Ishikawa Y, Fukushima H

📝 환자 설명용 한 줄

[INTRODUCTION] Epithelioid angiomyolipoma is a subtype of perivascular epithelioid cell tumors that may exhibit malignant behavior.

이 논문을 인용하기

↓ .bib ↓ .ris
APA Shimoda H, Fukuda S, et al. (2026). Durable Disease Control With Nivolumab in Malignant Epithelioid Angiomyolipoma: A Case Report.. IJU case reports, 9(2), e70170. https://doi.org/10.1002/iju5.70170
MLA Shimoda H, et al.. "Durable Disease Control With Nivolumab in Malignant Epithelioid Angiomyolipoma: A Case Report.." IJU case reports, vol. 9, no. 2, 2026, pp. e70170.
PMID 42022172 ↗
DOI 10.1002/iju5.70170

Abstract

[INTRODUCTION] Epithelioid angiomyolipoma is a subtype of perivascular epithelioid cell tumors that may exhibit malignant behavior. While mammalian target of rapamycin inhibitors are commonly used for systemic treatment, the efficacy of immune checkpoint inhibitors remains unclear.

[CASE PRESENTATION] A 58-year-old man was diagnosed with epithelioid angiomyolipoma after partial nephrectomy of a right renal mass. The tumor recurred locally, and multiple lung metastases developed despite surgical resection. Nivolumab was initiated after disease progression on everolimus, resulting in durable disease control for over 3 years. Immunohistochemistry revealed high PD-L1 expression and CD8+ T-cell infiltration within the primary tumor.

[CONCLUSION] Immune checkpoint inhibitors may be effective treatment options for malignant epithelioid angiomyolipoma with PD-L1 expression and CD8+ T-cell infiltration.

🏷️ 키워드 / MeSH 📖 같은 키워드 OA만

🏷️ 같은 키워드 · 무료전문 — 이 논문 MeSH/keyword 기반

🟢 PMC 전문 열기